Increased Fat Absorption from Enteral Formula Through an In-line Digestive Cartridge in Patients with Cystic Fibrosis

Steven Freedman, David Orenstein, Philip Black, Perry Brown, Karen McCoy, John Stevens, Danica Grujic, Russell Clayton

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objectives: Supplemental enteral nutrition (EN) is used by approximately 12% of people with cystic fibrosis (CF). The objective of this study was to evaluate the safety, tolerability, and fat absorption of a new in-line digestive cartridge (Relizorb) that hydrolyzes fat in enteral formula provided to patients with CF. Methods: Patients with CF receiving EN participated in a multicenter, randomized, double-blind, crossover trial with an open-label safety evaluation period. Plasma omega-3 fatty acid (FA) concentrations were measured and used as markers of fat absorption. Gastrointestinal symptoms were recorded to evaluate safety and tolerability. Information regarding the effect of EN on appetite and breakfast consumption was also collected. Results: Before study entry, participants had received EN for a mean of 6.6 years at a mean volume of approximately 800mL, yet had a mean body mass index of only 17.5kg/m 2 and omega-3 FA plasma concentrations were only 60% of levels found in normal healthy subjects. Compared with placebo, cartridge use resulted in a statistically significant 2.8-fold increase in plasma omega-3 FA concentrations. There were no adverse experiences associated with cartridge use, and a decrease in the frequency and severity of most symptoms of malabsorption was observed with cartridge use. Participants reported increased preservation of appetite and breakfast consumption with cartridge use compared with their pre-study regimen. Conclusions: Use of this in-line digestive cartridge was safe and well tolerated, and resulted in significantly increased levels of plasma omega-3 FA used with enteral formula, suggesting an overall increased fat absorption.

Original languageEnglish (US)
Pages (from-to)97-101
Number of pages5
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume65
Issue number1
DOIs
StatePublished - Jul 1 2017

Fingerprint

Omega-3 Fatty Acids
Enteral Nutrition
Cystic Fibrosis
Small Intestine
Fats
Breakfast
Appetite
Safety
Cross-Over Studies
Healthy Volunteers
Body Mass Index
Placebos

Keywords

  • enteral nutrition
  • fat malabsorption
  • fatty acid
  • omega-3
  • pancreatic enzyme replacement therapy
  • Relizorb

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Gastroenterology

Cite this

Increased Fat Absorption from Enteral Formula Through an In-line Digestive Cartridge in Patients with Cystic Fibrosis. / Freedman, Steven; Orenstein, David; Black, Philip; Brown, Perry; McCoy, Karen; Stevens, John; Grujic, Danica; Clayton, Russell.

In: Journal of Pediatric Gastroenterology and Nutrition, Vol. 65, No. 1, 01.07.2017, p. 97-101.

Research output: Contribution to journalArticle

Freedman, Steven ; Orenstein, David ; Black, Philip ; Brown, Perry ; McCoy, Karen ; Stevens, John ; Grujic, Danica ; Clayton, Russell. / Increased Fat Absorption from Enteral Formula Through an In-line Digestive Cartridge in Patients with Cystic Fibrosis. In: Journal of Pediatric Gastroenterology and Nutrition. 2017 ; Vol. 65, No. 1. pp. 97-101.
@article{2d13e79ee2314fc481508f50471f28d9,
title = "Increased Fat Absorption from Enteral Formula Through an In-line Digestive Cartridge in Patients with Cystic Fibrosis",
abstract = "Objectives: Supplemental enteral nutrition (EN) is used by approximately 12{\%} of people with cystic fibrosis (CF). The objective of this study was to evaluate the safety, tolerability, and fat absorption of a new in-line digestive cartridge (Relizorb) that hydrolyzes fat in enteral formula provided to patients with CF. Methods: Patients with CF receiving EN participated in a multicenter, randomized, double-blind, crossover trial with an open-label safety evaluation period. Plasma omega-3 fatty acid (FA) concentrations were measured and used as markers of fat absorption. Gastrointestinal symptoms were recorded to evaluate safety and tolerability. Information regarding the effect of EN on appetite and breakfast consumption was also collected. Results: Before study entry, participants had received EN for a mean of 6.6 years at a mean volume of approximately 800mL, yet had a mean body mass index of only 17.5kg/m 2 and omega-3 FA plasma concentrations were only 60{\%} of levels found in normal healthy subjects. Compared with placebo, cartridge use resulted in a statistically significant 2.8-fold increase in plasma omega-3 FA concentrations. There were no adverse experiences associated with cartridge use, and a decrease in the frequency and severity of most symptoms of malabsorption was observed with cartridge use. Participants reported increased preservation of appetite and breakfast consumption with cartridge use compared with their pre-study regimen. Conclusions: Use of this in-line digestive cartridge was safe and well tolerated, and resulted in significantly increased levels of plasma omega-3 FA used with enteral formula, suggesting an overall increased fat absorption.",
keywords = "enteral nutrition, fat malabsorption, fatty acid, omega-3, pancreatic enzyme replacement therapy, Relizorb",
author = "Steven Freedman and David Orenstein and Philip Black and Perry Brown and Karen McCoy and John Stevens and Danica Grujic and Russell Clayton",
year = "2017",
month = "7",
day = "1",
doi = "10.1097/MPG.0000000000001617",
language = "English (US)",
volume = "65",
pages = "97--101",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Increased Fat Absorption from Enteral Formula Through an In-line Digestive Cartridge in Patients with Cystic Fibrosis

AU - Freedman, Steven

AU - Orenstein, David

AU - Black, Philip

AU - Brown, Perry

AU - McCoy, Karen

AU - Stevens, John

AU - Grujic, Danica

AU - Clayton, Russell

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Objectives: Supplemental enteral nutrition (EN) is used by approximately 12% of people with cystic fibrosis (CF). The objective of this study was to evaluate the safety, tolerability, and fat absorption of a new in-line digestive cartridge (Relizorb) that hydrolyzes fat in enteral formula provided to patients with CF. Methods: Patients with CF receiving EN participated in a multicenter, randomized, double-blind, crossover trial with an open-label safety evaluation period. Plasma omega-3 fatty acid (FA) concentrations were measured and used as markers of fat absorption. Gastrointestinal symptoms were recorded to evaluate safety and tolerability. Information regarding the effect of EN on appetite and breakfast consumption was also collected. Results: Before study entry, participants had received EN for a mean of 6.6 years at a mean volume of approximately 800mL, yet had a mean body mass index of only 17.5kg/m 2 and omega-3 FA plasma concentrations were only 60% of levels found in normal healthy subjects. Compared with placebo, cartridge use resulted in a statistically significant 2.8-fold increase in plasma omega-3 FA concentrations. There were no adverse experiences associated with cartridge use, and a decrease in the frequency and severity of most symptoms of malabsorption was observed with cartridge use. Participants reported increased preservation of appetite and breakfast consumption with cartridge use compared with their pre-study regimen. Conclusions: Use of this in-line digestive cartridge was safe and well tolerated, and resulted in significantly increased levels of plasma omega-3 FA used with enteral formula, suggesting an overall increased fat absorption.

AB - Objectives: Supplemental enteral nutrition (EN) is used by approximately 12% of people with cystic fibrosis (CF). The objective of this study was to evaluate the safety, tolerability, and fat absorption of a new in-line digestive cartridge (Relizorb) that hydrolyzes fat in enteral formula provided to patients with CF. Methods: Patients with CF receiving EN participated in a multicenter, randomized, double-blind, crossover trial with an open-label safety evaluation period. Plasma omega-3 fatty acid (FA) concentrations were measured and used as markers of fat absorption. Gastrointestinal symptoms were recorded to evaluate safety and tolerability. Information regarding the effect of EN on appetite and breakfast consumption was also collected. Results: Before study entry, participants had received EN for a mean of 6.6 years at a mean volume of approximately 800mL, yet had a mean body mass index of only 17.5kg/m 2 and omega-3 FA plasma concentrations were only 60% of levels found in normal healthy subjects. Compared with placebo, cartridge use resulted in a statistically significant 2.8-fold increase in plasma omega-3 FA concentrations. There were no adverse experiences associated with cartridge use, and a decrease in the frequency and severity of most symptoms of malabsorption was observed with cartridge use. Participants reported increased preservation of appetite and breakfast consumption with cartridge use compared with their pre-study regimen. Conclusions: Use of this in-line digestive cartridge was safe and well tolerated, and resulted in significantly increased levels of plasma omega-3 FA used with enteral formula, suggesting an overall increased fat absorption.

KW - enteral nutrition

KW - fat malabsorption

KW - fatty acid

KW - omega-3

KW - pancreatic enzyme replacement therapy

KW - Relizorb

UR - http://www.scopus.com/inward/record.url?scp=85021846403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021846403&partnerID=8YFLogxK

U2 - 10.1097/MPG.0000000000001617

DO - 10.1097/MPG.0000000000001617

M3 - Article

VL - 65

SP - 97

EP - 101

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 1

ER -